Jan
16
FDA Approval for Savella
Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran hydrochloride), a selective serotonin and norepinephrine dual reuptake inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the management of Fibromyalgia Syndrome (Fibro).
more